Posted: November 7th, 2017
Generics (UK) Limited trading as Mylan & Ors. v Yeda Research and Development Company Limited & Ors, High Court, London, UK, 26 October 2017, Neutral Citation Number: [2017] EWHC 2692 (Pat) This case was brought by the Claimants (Mylan and Synthon) seeking revocation of EP (UK) 2,949,335 (“EP’335”), a patent owned by Yeda and exclusively […]
READ MOREPosted: November 2nd, 2017
Sandoz B.V. v. Astrazeneca AB, Court of Appeal The Hague, The Netherlands, 31 October 2017, Case No. 200.200.332/01, with thanks to Willem Hoyng and Theo Blomme, HOYNG ROKH MONEGIER, for submitting the case including an English and German translation thereof Astrazeneca markets FASLODEX which is used for the treatment of oestrogen hormone dependent breast cancers. […]
READ MOREPosted: October 5th, 2017
Celltrion Inc, v. F. Hoffmann-La Roche AG, Biogen Inc. and Genentech Inc., District Court of the Hague, 27 September 2017, Case No. ECLI:NL:RBDHA:2017:11301 Patent revoked due to lack of novelty. Priority can not be invoked since the priority right was not validly transferred. A copy of the decision can be read here.
READ MOREPosted: September 29th, 2017
Asetek A/S v. Cooler Master Europe B.V., District Court of The Hague, the Netherlands, 20 September 2017, Case number C/09/515892 / HA ZA 16-906 Asetek is the holder of the European patent EP 1 923 771 B1 (“EP ‘771”) entitled “Cooling system for a computer system”. The patent was filed on 8 November 2004 relying […]
READ MOREPosted: September 22nd, 2017
SA FN Herstal v. Heckler & Koch GmbH, Tribunal de Commerce Francophone de Bruxelles, 28 April 2017 Combination invention vs. mere aggregation of features in patent law On 28 April 2017, the French-speaking Court of commerce of Brussels rendered a judgment in a patent case opposing the Belgian weapon manufacturer FN Herstal to its German […]
READ MOREPosted: July 17th, 2017
Swiss Pharma International v. Biogen MA Inc., District Court The Hague, the Netherlands, 12 July 2017, ECLI:NL:RBDHA:2017:7628 Biogen holds EP 1485127, which relates to the treatment of Multiple Sclerosis (“MS”). Swiss Pharma seeks to invalidate the Dutch part of the patent. Claims 1, 3 and 4 are invalidated due to lack of novelty as these […]
READ MOREPosted: July 5th, 2017
Intermarine S.p.A. (formerly Rodriquez Cantieri Navali S.p.A.) v. CMC Marine S.r.l.. Court of Appeal of Turin, Italy, 22 June 2017, Judgement no. 106/2016 With its writ of summons in the first instance proceedings, Intermarine demanded the Court of Turin a declaration of invalidity of a utility model owned by CMC. Said utility model related to […]
READ MOREPosted: June 9th, 2017
Carl Zeiss Meditec AG v. VSY Biotechnology B.V. et al., District Court The Hague, The Netherlands, 7 June 2017, Case No. ECLI:NL:RBDHA:2017:6136 European Patent on an intraocular (implantable) lens. Interpretation of claims. The Dutch part of the patent is valid: the hurdles of novelty, inventive step and enablement were all taken successfully. The patent is […]
READ MOREPosted: March 29th, 2017
Koninklijke Philips NV v. Wiko SAS, Case no. ECLI:NL:RBDHA:2017:2719, Koninklijke Philips NV v. Archos S.A., Case no. ECLI:NL:RBDHA:2017:2720, Koninklijke Philips NV v. Asustek Computer Inc., Asus Europe B.V. and Asus Holland B.V., Case no. ECLI:NL:RBDHA:2017:2721, District Court The Hague, 22 March 2017 The present dispute concerns an alleged infringement of the rights of Koninklijke Philips […]
READ MORE